argenex SE (NASDAQ:ARGX) Receives $986.78 Consensus PT from Brokerages

argenex SE (NASDAQ:ARGX) has received an average recommendation of “Moderate Buy” from the twenty-four research firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation, eighteen have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $986.7778.

A number of research analysts have commented on ARGX shares. Evercore ISI raised their price target on shares of argenex from $775.00 to $910.00 and gave the stock an “outperform” rating in a research note on Friday, October 31st. Zacks Research downgraded argenex from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 22nd. Piper Sandler boosted their price target on argenex from $820.00 to $930.00 and gave the company an “overweight” rating in a research note on Tuesday, November 4th. Weiss Ratings reiterated a “hold (c)” rating on shares of argenex in a research report on Wednesday, January 21st. Finally, Citigroup cut their price objective on argenex from $1,124.00 to $1,091.00 and set a “buy” rating for the company in a report on Thursday, January 8th.

Hedge Funds Weigh In On argenex

Several institutional investors have recently added to or reduced their stakes in ARGX. Morse Asset Management Inc boosted its position in argenex by 65.0% in the fourth quarter. Morse Asset Management Inc now owns 660 shares of the company’s stock valued at $555,000 after buying an additional 260 shares in the last quarter. Advisors Preferred LLC raised its stake in shares of argenex by 12.3% in the fourth quarter. Advisors Preferred LLC now owns 585 shares of the company’s stock valued at $491,000 after acquiring an additional 64 shares during the last quarter. Oppenheimer & Co. Inc. raised its stake in shares of argenex by 2.8% in the fourth quarter. Oppenheimer & Co. Inc. now owns 442 shares of the company’s stock valued at $372,000 after acquiring an additional 12 shares during the last quarter. Values First Advisors Inc. acquired a new position in shares of argenex in the 4th quarter worth approximately $862,000. Finally, R Squared Ltd bought a new stake in argenex during the 4th quarter worth approximately $395,000. 60.32% of the stock is owned by institutional investors.

argenex Stock Performance

NASDAQ:ARGX opened at $835.68 on Tuesday. The company has a 50-day moving average of $850.70 and a 200-day moving average of $786.24. The company has a market capitalization of $51.71 billion, a price-to-earnings ratio of 35.88, a PEG ratio of 0.55 and a beta of 0.37. argenex has a 52 week low of $510.05 and a 52 week high of $934.62.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.